GlobeNewsWire
13 Jun 2026, 20:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ascendis Pharma's Phase 3 PaTHway Trial showed TransCon PTH demonstrated sustained efficacy and safety over a three-and-a-half-year period (Week 182). — Long-term Phase 3 success reduces regulatory and clinical risk, supporting the commercial viability of the drug.
+0.60TransCon PTH enabled patients to achieve independence from conventional therapies, including active vitamin D and calcium supplements. — Replacing standard-of-care therapy with a single-drug alternative creates a strong competitive advantage and higher market penetration.
+0.50The trial reported normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density through Week 182. — Broad biochemical normalization validates the drug's systemic action, making it more attractive to prescribers.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced positive Phase 3 trial data showing sustained efficacy and safety for its TransCon PTH treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
